 Source: rafapress Shutterstock Bluebird Bio NASDAQ: BLUE stock is on the move Thursday following U.S. Food and Drug Administration FDA approval for ZYNTEGLO. ZYNTEGLO is a gene therapy designed for patients that require regular red blood cell RBC transfusions. 